SVA
vs
S
S&P TSX Composite Index (Canada)
SVA
Over the past 12 months, SVA has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +29% growth.
Stocks Performance
SVA vs S&P TSX Composite Index (Canada)
Performance Gap
SVA vs S&P TSX Composite Index (Canada)
Performance By Year
SVA vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sernova Corp
Glance View
Sernova Corp. is a clinical stage regenerative medicine company. The company is headquartered in London, Ontario. The firm is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. The company is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device, protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. The company is also evaluating Cell Pouch for the treatment of patients with hemophilia A.
